Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by immune malfunction. Disease targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency in cystic fibrosis patients, and inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
IN THE NEWS
|
Mar 13, 2023
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
|
|
Mar 10, 2023
First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
|
|
Mar 09, 2023
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
|
